A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma ; volume:9 ; number:1 ; day:20 ; month:4 ; year:2024 ; pages:1-16 ; date:12.2024
Signal transduction and targeted therapy ; 9, Heft 1 (20.4.2024), 1-16, 12.2024
- Urheber
-
Zhu, Wei
Zhang, Zhiming
Chen, Jinzhang
Chen, Xiaolan
Huang, Lei
Zhang, Xiaoyong
Huang, Xuan
Ma, Na
Xu, Weikang
Yi, Xuan
Lu, Xinyu
Fu, Xin
Li, Siwei
Mo, Guoheng
Wang, Yiyue
Yuan, Guosheng
Zang, Mengya
Li, Qi
Jiang, Xiaotao
He, Yajing
Wu, Sha
He, Yukai
Li, Yongyin
Hou, Jinlin
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41392-024-01792-6
- URN
-
urn:nbn:de:101:1-2407022104221.086412132865
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zhu, Wei
- Zhang, Zhiming
- Chen, Jinzhang
- Chen, Xiaolan
- Huang, Lei
- Zhang, Xiaoyong
- Huang, Xuan
- Ma, Na
- Xu, Weikang
- Yi, Xuan
- Lu, Xinyu
- Fu, Xin
- Li, Siwei
- Mo, Guoheng
- Wang, Yiyue
- Yuan, Guosheng
- Zang, Mengya
- Li, Qi
- Jiang, Xiaotao
- He, Yajing
- Wu, Sha
- He, Yukai
- Li, Yongyin
- Hou, Jinlin
- SpringerLink (Online service)
Ähnliche Objekte (12)
T cell receptor-engineered T cells for leukemia immunotherapy
TCR engineered T cells for solid tumor immunotherapy
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
T-cell receptor-engineered T cells for cancer treatment: current status and future directions
Developing new chimeric antigen receptor (CAR)-engineered natural killer cells targeting ovarian cancer stem cells
Generation of dual T cell receptor (TCR) T cells by TCR gene transfer for adoptive T cell therapy
Synthetic Artificial Apoptosis‐Inducing Receptor for On‐Demand Deactivation of Engineered Cells
Recognition of renal cell carcinoma by CD8+ and CD4+ TCR-engineered T lymphocytes
TCR‐engineered T cells: A model of inducible TCR expression to dissect the interrelationship between two TCRs
T cell receptor-engineered T cells for leukemia immunotherapy
TCR engineered T cells for solid tumor immunotherapy
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
T-cell receptor-engineered T cells for cancer treatment: current status and future directions
Developing new chimeric antigen receptor (CAR)-engineered natural killer cells targeting ovarian cancer stem cells
Generation of dual T cell receptor (TCR) T cells by TCR gene transfer for adoptive T cell therapy
Synthetic Artificial Apoptosis‐Inducing Receptor for On‐Demand Deactivation of Engineered Cells
Recognition of renal cell carcinoma by CD8+ and CD4+ TCR-engineered T lymphocytes
TCR‐engineered T cells: A model of inducible TCR expression to dissect the interrelationship between two TCRs
T cell receptor-engineered T cells for leukemia immunotherapy
TCR engineered T cells for solid tumor immunotherapy
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
T-cell receptor-engineered T cells for cancer treatment: current status and future directions
Developing new chimeric antigen receptor (CAR)-engineered natural killer cells targeting ovarian cancer stem cells
Generation of dual T cell receptor (TCR) T cells by TCR gene transfer for adoptive T cell therapy
Synthetic Artificial Apoptosis‐Inducing Receptor for On‐Demand Deactivation of Engineered Cells
Recognition of renal cell carcinoma by CD8+ and CD4+ TCR-engineered T lymphocytes